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Abstract  
The relationship between HIV and AIDS and poor nutrition has been well established. Poor nutrition hastens the progression of 
HIV infection to AIDS. The rising pandemic of HIV and AIDS and high toxicity associated with anti-retroviral use are major factors that have 
compelled research to explore traditional herbal medicines as potential alternatives or supplements to anti-retroviral agents. A Phase I clinical trial 
was conducted on IMUNITI Wellness Pack, a herbal product with putative immune-modulating properties. The product is a combination of 7 
herbal preparations, minerals, vitamins, and a specially formulated soya-maize meal porridge and a bottle of water purifier. The aim was to 
evaluate the safety and tolerability of IMUNITI, with a purpose of developing it for use in HIV-infected patients. The phase I study was conducted 
at the MRC clinic in Botha’s hill and the study lasted 5 weeks from date of participant dosing. The study was a randomised blinded placebo-
controlled phase I clinical trial conducted on 48 healthy males. The participants were randomly divided into 4 groups of 12. The 3 groups received 
different escalating doses of IMUNITI while the forth group received placebo tablets. Participants consumed IMUNITI daily for a period of 5 weeks. 
Assessments were done at baseline, week 1 and week 5 to determine the safety parameters in all participants. In this study, IMUNITI did not 
show any safety concerns. In all study participants, there were no significant changes above the upper limit of the reference ranges of the 
laboratory tests for full blood count, INR, renal and biochemical safety parameters. IMUNITI was well tolerated. Furthermore, the nutritional 
content analysis of IMUNITI showed that it is a high kilojoule, high protein content product which contains a mixture of sugars, vitamins, traces of 
calcium, phosphorus and minerals.  
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Introduction 
 
An estimated 5.6 million people were living with HIV and AIDS in South Africa in 2009, more than in any other country (UNAIDS 2010). HIV and 
AIDS accounted for 310,000 deaths in South Africa, resulting in 1.9 million AIDS orphans, of which 330,000 were living with HIV. Prevalence is 
high among those aged 15-49; almost one-in-three women aged 25-29, and over a quarter of men aged 30-34 are living with HIV (HRSC 2009; 
Statistics South Africa 2008, 2010). 
South Africa has the largest antiretroviral therapy programme in the world, but given the magnitude of the epidemic, access to 
treatment is low (Meyer-Rath, G et al., 2010). Only about 37% of infected people were receiving treatment for HIV. Meanwhile at least 30 people 
were dying daily due to their inability to access ARVs (Cornell, 2010; Mail and Guardian 2009). Also, starting treatment at a CD4 count of <350 
cells/mm3 according to the WHO guidelines led to increased demand for ARVs (WHO/UNAIDS/UNICEF 2010). The increased deployment of 
ARVs and an influx of new patients put a strain on the administrative capacity of health authorities, which lead to poor service delivery (Peris, 
2010; Health-e 2010). This inadequate supply of ARVs lead to interrupted treatment, which together with the non-adherence to the life-time long 
therapy, promote risk for drug resistance (Krakovska et al., 2007; Harrison, 2009., DoH 2010). These challenges emphasise the need for more 
affordable, easily accessible short term treatment for HIV and AIDS. One unexplored avenue is traditional medicines and development of 
medicinal herbal products that have antiviral and immune boosting properties. Strengthening the use of scientifically validated traditional 
medicines in a comprehensive scientific and clinical-based approach, and provision of good nutrition to HIV and AIDS patients could result in 
drastic reduction of the burden of HIV and AIDS. 
The aim of the study presented here was to evaluate the safety and tolerability of IMUNITI Wellness Pack, with the aim of further 
developing it for use in HIV-infected patients. IMUNITI Wellness Pack is a nutritional herbal product with putative immune-modulating properties. It 
is a combination of 7 nutritional and herbal medicinal plants, namely, Sutherlandia, African Potato, Chinese Green Tea, Spirulina, Rooibos 
supplemented with selenium and Zinc, and with the Aloe vera juice which is supplemented with Vitamin C. In addition to these components, the 
pack contains a specially formulated soya-maize meal porridge and a bottle of water purifier. There are some various anecdotal evidences of the 
health benefits of IMUNITI Wellness Pack on HIV infected individuals. This evidence can, however, not be used as a basis for the supply of 
IMUNITI to the larger public. Credible scientific evidence supporting these anecdotes and the safety of the product under controlled conditions 
need to be provided if the product is to be made available to the public (De Smet, 1995).  
 
Materials and Methods 
Study Participants 
 
The study was conducted at the MRC clinical trial site in Valley of Thousand Hills, Botha’s Hill in KwaZulu Natal. Forty eight (48)  
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healthy male volunteers between the ages of 18 to 45 were recruited for the study. Participants were recruited from neighbouring villages in 
Bothas Hill, Kwa-Zulu Natal, South Africa.  All subjects were in good health as determined by medical history, physical examination, vital signs, 
and clinical laboratory measurements. To be included in the study, the participants had to be able to give informed consent, test sero negative for 
HIV and be between ≥18 and ≤ 45years of age. The exclusion criteria are summarized as follows: 1) History suggestive of tuberculosis (TB), and 
Diabetes mellitus. 2) On treatment for chronic illness e.g. diabetes, arthritis, TB etc. 3) On medication for immune modulation, herbal medicines, 
traditional medicines or multivitamins. 4) Excessive Smoking (nicotine dependence). 5) Excessive alcohol dependence. 6) Sero-positive for HIV.   
The study was approved by the South African Medical Research Council Ethics Committee. All participants included in the trial gave written prior 
informed consent to participate. Participants had the right to withdraw at any moment by immediately contacting the investigators to inform them, 
without obligation to provide reasons. 
 
Study design 
 
This study employed a double-blind placebo-controlled design. The product was tested at three different doses. Participants were 
randomly assigned to one of four treatment groups of 12  ( Table 2).. The first group received a standard recommended daily dose of the 
supplements (Table 1). The second group and third group each received twice and thrice the recommended daily dose, respectively. The fourth 
group received the standard IMUNITI Wellness Pack but with placebo tablets containing insipient only. Groups 1 – 3 received 150 ml Aloe Vera 
juice, but diluted for Groups 1 & 2 (Group 1; 50 ml juice + 100 ml Aloe Vera flavoured water and Group 2; 100 ml juice + 50 ml Aloe Vera flavoured 
water). Group 4 received 150 ml Aloe Vera flavoured water to blind the treatment. Aloe Vera juice was diluted at the manufacturing stage at Impilo 
drugs, Kwa-Zulu Natal. 
Participants met daily at pre-determined venues to take the study medication under the supervision of the field monitor.The study 
medication was administered between 7:00 and 10:00 hrs daily for 5 weeks. The porridge included in the IMUNITI Wellness Pack was standard 
for all four groups. The study blinding was maintained by making the placebo tablets similar in appearance to the active study medication and by 
using Aloe Vera flavoured water. 
 
Table 1. Recommended daily does of IMUNITI Wellness Pack  
Constituent Strength Recommended daily Total Daily intake 
Sutherlandia 300mg 2 tablets 600mg 
African potato 300mg 1 tablet 300mg 
Rooibos incl. 
Selenium 
Zinc 
175mg 
0.2mg 
50mg 
1 tablet with food 
 
 
175mg 
0.2mg 
50mg 
Pure Spirulina 500mg 1 tablet 500mg 
Chinese Green Tea 150mg 1 tablet 150mg 
Aloe vera 
+ Vit C 
400mg per 50ml 
60mg per 50ml 
Take 50ml daily 
 
 
60mg 
Porridge (Soya + Maize) or 50g 
100g 
2 heaped tablespoons with water or milk twice daily 
4 heaped tablespoons with water or milk 
 
Blue Gold natural water purifier Drops   
Tap or bottled water  1 drop per 1 litre and left for 1 minute  
Total daily consumption 1835.2mg 
 
Table 2. Study design and dosage; three study groups received Wellness Pack daily at three different doses while the fourth group received 
placebo tablets. Porridge was standard for all groups. 
Group Participants 
(n=48) 
Dose/day 
  # Wellness Pack/ day (Active) Placebo 
Tablets 
Aloe Vera (mL) Porridge (g) 
1 12 ecommended (Recommended as in pack + 12 place
tablets 
12 50 mL juice + 
100 mL water* 
100 
2 12 x (Recommended Wellness Pack but twice number 
tablets + 6 placebo tablets) 6 
100 mL juice + 
50 mL water 
100 
3 12 x  (Recommended Wellness Pack but with three tim
the number of tablets) 
0 150 mL juice 
 
100 
4 12 acebo (Recommended Wellness Pack with 18 place
tablets 
18 150 mL  water 100 
 
 
Safety Assessments 
 
Assessment of product safety included clinical observation and monitoring of haematological and biochemical parameters; liver 
function tests as measured by ALT, AST, GGT and LDH, and renal function tests as measured by Urea, Creatinine and electrolytes clearance. 
Physical examinations, anthropometry, vital sign measurements and blood sampling for clinical laboratory testing were performed at a screening 
assessment, which occurred within 28 days prior to baseline assessments and administration of the first dose of study medication. Similar follow-
up assessments were done at week 1 and week 5. All observed and volunteered adverse events (AEs) were recorded daily by field monitors 
using health assessment questionnaires and by a clinician on standardized case report forms. An independent monitoring safety committee – 
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Data and Safety Monitoring Board (DSMB) – was created to evaluate the safety of the product by reviewing AEs encountered. The Division of 
AIDS Table for grading the severity of Adult Adverse Events (DAIDS grading table) wherein a grading severity scale is provided for each possible 
laboratory test was utilized for AE reporting in this study. Arrangements were made with hospital management at Grey’s Hospital, 
Pietermaritzburg, for participants needing emergency treatment or hospitalisation.  
 
Data analysis 
 
The effect of each dose at different visits on the clinical, haematology and biochemical variables, were assessed by an Analysis of 
Variance (ANOVA).  Individual comparisons between groups were made using Scheffe’s acceptance test for post hoc comparisons. A p-value < 
0.05 was indicative of statistical significance. SAS version 9.2 was used for all analysis, including the basic descriptive statistics. 
 
Nutritional content of the IMUNITI Wellness Pack 
 
The nutritional content of IMUNIT wellness pack was evaluated without the porridge. The evaluation was outsourced to the 
Agricultural Research Council (ARC) analysing laboratory, which holds SANAS accreditation for analyses and an ASM number. The samples 
received were thoroughly mixed before analysis as per manufacturer’s instruction of reconstituting the IMUNITI Pack.  
 
Results 
Participants 
 
A total of 90 male participants were available for screening for the study. Participants that tested positive for HIV, had grade 3 
laboratory abnormalities or tested positive for hepatitis B were excluded. A total of 48 participants were successfully recruited and only 46 
completed the study. Two participants dropped out of the study due to reasons not related to the study drug. There was 95.8% adherence to the 
study. 
 
Results of laboratory tests 
 
The DAIDS grading table was used as criteria for AE reporting. In general, the volunteers showed values within the limits of 
normality in the results of the clinical tests in the all visits throughout the study. There were no significant changes in all study participants across 
all dosage groups in the haemoglobin concentration, the MCV values, iron and ferritin levels. IMUNITI had no effect on the metabolism B12, folate 
and the absorption of iron from the gastrointestinal tract. INR values were within limits showing that IMUNITI did not inhibit vitamin K absorption in 
the gastrointestinal tract. None of the biochemical safety parameters were above a grade 2 according to the DAIDS table. Random glucose levels 
were within normal ranges.  
 
Adverse events 
 
No deaths or serious AEs occurred. No AEs were reported by the field monitors. No study participants reported any significant 
side-effects such as headaches, nausea, vomiting, diarrhoea, rash, fatigue and sleep disturbances. No AEs or significant changes in physical 
examination were reported in the Case Report Forms. The overall abnormalities in the biochemical and haematological values using the DAIDS 
table were considered moderate by study Principle Investigator. There we were no defaulters or discontinuations reported. There was 100% 
compliance to the study medication and 95.8% adherence to the study. 
 
Nutritional content of the IMUNITI pack 
 
The nutritional content of the IMUNITI Wellness Pack without the porridge is shown in Table 3 
 
Table 3.  The nutritional content of IMUNITI.  The results relate to RDA of adults above the age of 12. and show the recommended daily dose of 
the IMUNITI Wellness Pack. Where applicable RDA figures are included for comparison only. 
 
Analysis 
 
Unit 
 
Sample  IMUNITI 
 
RDA 
 
   Male Adults (4 Yrs and oldeMaximum Daily consumption of IMUNI
(1835.2mg) 
Calcium  0.22 800 – 1300mg  
Phosphorous  0.29   
Dry matter  94.14   
Moisture  5.86   
Fat (ether extraction)  7.39   
NDFIN  0.045   
Organic matter (Calculated) 89.72   
Starch  35.40   
Water Soluble Carbohydrates  26.54   
Total non- structural carbohydrates  60.40   
Carbohydrates (calculated) 64.20 13g/100g  
Sugars    
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Glucose g/100g Not detected   
Fructose g/100g 0.23  0.0042 
Sucrose g/100g 19.28  0.3540 
Maltose g/100g 1.11  0.0204 
Lactose g/100g Not detected   
Rafinose g/100g 1.24  0.0228 
Stachiose % 1.51   
Vitamins     
Vit A mg/100g 0.27 400 – 700mg 0.0037 
Vit B1 mg/100g 0.07 0.6 - 1.2mg 0.0013 
Vit B2 mg/100g 1.20 0.6 -  1.1mg 0.0022 
Vit C mg/100g 22.25 25 – 100mg 0.0408 
Vit E mg/100g 5.60 7- 15mg tec 0.1028 
Amino acids     
Arginine g/100g 1.18  0.0217 
Serine g/100g 0.67  0.0123 
Aspartic  Acid g/100g 1.18  0.0217 
Glutamic  Acid g/100g 2.74  0.0503 
Glycine g/100g 0.69  0.0127 
Threonine g/100g 0.76  0.0140 
Alanine g/100g 0.62  0.0118 
Tyrosine g/100g 0.72 14 – 24mg/kg 0.0132 
Proline g/100g 1.04  0.0191 
HO-Proline g/100g 0.01  0.0002 
Metheonine g/100g 0.15 13 – 24mg/kg 0.0028 
Valine g/100g 0.85 13 – 28mg/kg 0.0156 
Phenylalanine g/100g 0.82 14 – 28mg/kg 0.0151 
Isoleucine g/100g 0.72 10 – 28mg/kg 0.0132 
Leucine g/100g 1.30 14 – 44mg/kg 0.0239 
Histidine g/100g 1.39 29mg/kg(infants only) 0.2551 
Lysine g/100g 0.97 12 – 49mg/kg 0.0178 
Cysteine g/100g 0.12 13-24mg/kg 0.0022 
Tryptophan g/100g 0.19 3 – 4mg/kg 0.0035 
Protein % 18.13 56g*  
Micro elements     
Aluminium Mg/100g 1.90  0.0349 
Boron Mg/kg 11.50 UL = 20mg 0.0211 
Calcium Mg/100 159  800 – 1300mg 2.918 
Chloride Mg/100g 878 1..9 – 3.6g 16.11 
Chromium Mg/kg 1.03 15 - 35µg/100g 0.0019 
Cobalt Mg/kg 0.11  0.0002 
Flouride Mg/100g <15.0 1 – 4mg <0.2753 
Magnesium Mg/100g 118 130 – 420mg 2.1655 
Nitrate Mg/100g 20.80  3.8172 
Nitrite Mg/100g <20  <0.3670 
Phosphorus Mg/100g 367 3.8 – 4.7g 6.7352 
Potassium Mg/100g 574 1,2 – 1.5g 10.5340 
Sodium Mg/100g 813 Low 120mg/100g 14.920 
Sulphur Mg/100g 29.70  0.5451 
Sulphate Mg/100g 89  1.633 
Antimony Mg/kg <0.1  <0.0002 
Arsenic Mg/kg <0.1  <0.0002 
Barium Mg/kg 144  0.264 
Cadmium Mg/kg <0.1  <0.0002 
Copper Mg/kg 7.90 440 - 900µg 0.0145 
Iron Mg/kg 171 8 - 18mg 0.3138 
Lead Mg/kg 11.72  0.0022 
Manganese Mg/kg 14.50 2.3mg 0.0266 
Mercury Mg/kg 0.10  0.0002 
Molybdenum Mg/kg 0.93 45µg 0.0017 
Nickel Mg/kg 6.50 UL = 1.0mg 0.0119 
Nitrogen Mg/100g 3.24  0.0597 
Selenium Mg/kg <0.1 30 - 55µg <0.0002 
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The Wellness Pack has a high protein content (18%) with a composition of 10 essential amino acids and 9 non-essential amino acids.  The 
product has a low fat content of only 7.4% but a high content of starch (35.40%) and a mixture short chain sugars which contribute to its high 
kilojoule base (170kJ/100g).  Vitamins A, B, C and E, and presence of many micro elements, calcium and phosphorus add to the multi-nutritional 
value of IMUNITI.   
 
Conclusion 
 
In this study, IMUNITI did not show any safety concerns. There were no clinically significant consistent changes in laboratory 
parameters in the groups receiving IMUNITI compared to the Placebo group, over the 5 week study period. IMUNITI was well tolerated by all 3 
groups. IMUNITI is a high energy and high protein content product with a mixture of essential amino acids, useful Vitamins and minerals which 
may boost the immune system, and can therefore contribute to the recovery process in AIDS patients. Since the progression of HIV to AIDS 
especially in developing countries is exacerbated by poor nutrition and unhygienic environment, the product could be recommended as a basis for 
a sustainable nutritional component for wellness programmes especially in the rural settlements where majority of the population is stricken by 
poverty and lack of clean water.  
The consumption of Imuniti Wellness pack does not pose any danger in exceeding any of the RDA for all the product constituents analysed for. 
The heavy metal, pesticides and microbial levels were within acceptable WHO, BP, EMEA, EP and USP standards 
No Staphylococcus. aureus, Pseudomonas aeruginosa, Salmonella species and Escherichia coli were detected in the IMUNITI sample analysed 
and the microbial contamination testing results were all within the WHO specifications for traditional medicinal plants (WHO, 2007). 
The safety and nutritional content of studies of IMUNITI have given enough data to support the development of bigger scientific and clinical 
studies to now investigate its efficacy in patients infected with HIV-1. 
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Strontium Mg/kg 3  0.0055 
Tin Mg/kg 0.59  0.0011 
Titanium Mg/kg 5.58  0.0102 
Vanadium Mg/kg <0.3 UL = 1.8mg <0.0006 
Zinc Mg/kg 170 5 - 12mg 0.3120 
Fibre and Energy     
Fibre (crude) % 1.55 3g/100g  
Neutral detergent fibre % 4.20   
Dietary fibre (total) % 5.78 25 – 38g  
Insoluble dietary fibre % 8.31   
Soluble dietary fibre % Not detected   
In vitro digestibility % 87.73   
ME calculation MJ/Kg 12.79  0.0235 
Energy MJ/kg ASM 053 170kJ/100g 0.0326 
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